After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Allogene Therapeutics Inc is $457.09M. A total of 4.7 million shares were traded on the day, compared to an average of 5.35M shares.
In the most recent transaction, MESSEMER DEBORAH M. sold 13,313 shares of ALLO for 2.43 per share on Feb 18 ’25. After the transaction, the Director now owns 144,316 company shares. In a previous transaction on Feb 18 ’25, MESSEMER DEBORAH M. bought 13,313 shares at 2.43 per share.
Among the insiders who sold shares, Douglas Earl Martin disposed of 6,404 shares on Feb 03 ’25 at a per-share price of $1.71. This resulted in the SVP, General Counsel holding 587,848 shares of ALLO after the transaction. In another insider transaction, Parker Geoffrey M. sold 4,361 shares at $1.73 per share on Feb 03 ’25. Company shares held by the CHIEF FINANCIAL OFFICER now total 1,301,540.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ALLO has a high of $5.78 and a low of $1.32.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ALLO’s latest balance sheet shows that the firm has $457.30M in Cash & Short Term Investments as of fiscal 2021. There were $73.13M in debt and $47.91M in liabilities at the time. Its Book Value Per Share was $2.21, while its Total Shareholder’s Equity was $925.20M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.35.
